- Current report filing (8-K)
21 Mayo 2010 - 2:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2010
Winston Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51314
|
|
30-0132755
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
100 North Fairway Drive,
Suite 134
Vernon Hills, Illinois
|
|
60061
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(847) 362-8200
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
ITEM 1.01
|
|
Entry into a Definitive Material Agreement
|
(a)
|
|
Effective May 19, 2010, Pharmaceutical Financial Syndicate, LLC
(PFS), whose members include Dr. Joel E. Bernstein, the President
and Chief Executive Officer of Winston Pharmaceuticals, Inc. (the
Company), and Robert A. Yolles and Neal S. Penneys, directors of the
Company, executed a Stock Purchase Agreement (SPA) with Frost Gamma
Investments Trust (Frost Gamma), Subbarao Uppaluri, a director of
the Company, Steven D. Rubin and Jane Hsiao (collectively, the Frost
Group), to acquire 100% of the Companys capital stock (the
Acquisition) beneficially owned by all of the members of the Frost
Group consisting of an aggregate of 18,399,271 outstanding shares of
common stock and warrants to purchase an aggregate of 8,958,975 shares
of common stock (collectively, the Acquired Securities). As
consideration for the Acquired Securities, PFS paid the Frost Group an
aggregate amount of cash equal to $789,500 and executed non-recourse
promissory notes in favor of each of the members of the Frost Group in
the aggregate principal amount of $10,263,500 (the Promissory
Notes). 92.857% of the Acquired Securities (the Escrowed
Securities) were placed in escrow pursuant to the SPA and an escrow
agreement by and among PFS, the Frost Group and an escrow agent (the
Escrow Agreement) as security for the payment of the Promissory
Notes. The Escrowed Securities are subject to release to PFS in
proportion to its payment of principal under each of the Promissory
Notes.
|
|
|
|
As of the completion of the Acquisition, as the manager of PFS, Dr.
Bernstein is deemed to be the indirect beneficial owner of all of the
Acquired Securities, however Dr. Bernstein intends to disclaim
beneficial ownership of those Acquired Securities in which he does not
have a pecuniary interest through PFS pursuant to Rule 13d-4 of the
Securities Exchange Act of 1934, as amended.
|
|
|
|
Simultaneous with the Acquisition, the Company entered into a
Registration Rights Agreement with each of the members of the Frost
Group and PFS (the Registration Rights Agreement) and a Standstill
Agreement with the Frost Group, Dr. Bernstein and his spouse, Carole
Bernstein (the Standstill Agreement). Among other things, the
Registration Rights Agreement grants PFS and each of the members of
the Frost Group certain piggyback registration rights with respect to
the Acquired Securities in the event that the Company proposes to
register any class of its common stock under the Securities Act of
1933, as amended, for its own account or for the account of any holder
of its securities. Among other things, under the Standstill
Agreement, the Company has agreed not to enter into any agreement with
respect to its securities that is inconsistent with or violates the
rights granted to the parties to the Standstill Agreement under the
SPA or the Escrow Agreement, nor to elect or appoint any of Dr. Joel
E. Bernsteins adult children to serve on the Companys Board of
Directors for so long as the Promissory Notes remain outstanding,
except for such children as agree to be bound by the terms of the
Standstill Agreement. The foregoing descriptions of the Registration
Rights Agreement and the Standstill Agreement are summaries and are
qualified in their entirety by the terms and conditions of the
Registration Rights Agreement and the Standstill Agreement, copies of
which are attached as exhibits to this Current Report.
|
2
|
|
|
ITEM 5.02
|
|
Departure of Directors or Certain Officers: Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
|
(b)
|
|
See Item 1.01 herein above, which is incorporated herein by reference.
|
|
|
|
As provided in the SPA, and simultaneous with the Acquisition, three
of the Companys directors, namely Subbarao Uppaluri, Glenn Halpryn
and Curtis Lockshin, resigned as directors of the Company.
|
See Items 1.01 and 5.02 herein above, which are incorporated herein by reference.
|
|
|
ITEM 9.01
|
|
Financial Statements and Exhibits
|
(d) Exhibits
10.1
|
|
Registration Rights Agreement between Pharmaceutical Financial Syndicate, LLC, Frost Gamma
Investments Trust, Subbarao Uppaluri, Steven D. Rubin and Jane Hsiao, Ph.D.
|
|
10.2
|
|
Standstill Agreement between Joel E. Bernstein, Carole Bernstein, Frost Gamma Investments
Trust, Subbarao Uppaluri, Steven D. Rubin and Jane Hsiao, Ph.D.
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
Date: May 21, 2010
|
WINSTON PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ Joel E. Bernstein
|
|
|
|
Joel E. Bernstein, M.D.
|
|
|
|
Chief Executive Officer
|
|
4
EXHIBIT INDEX
10.1
|
|
Registration Rights Agreement between Pharmaceutical Financial Syndicate, LLC, Frost Gamma
Investments Trust, Subbarao Uppaluri, Steven D. Rubin and Jane Hsiao, Ph.D.
|
|
10.2
|
|
Standstill Agreement between Joel E. Bernstein, Carole Bernstein, Frost Gamma Investments
Trust, Subbarao Uppaluri, Steven D. Rubin and Jane Hsiao, Ph.D.
|
5
Winston Pharmaceuticals (CE) (USOTC:WPHM)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025
Winston Pharmaceuticals (CE) (USOTC:WPHM)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025
Real-Time news about Winston Pharmaceuticals Inc (CE) (OTCMarkets): 0 recent articles
Más de Artículos de Noticias